CDIO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.679

Open

2.540

VWAP

2.38

Vol

375.18K

Mkt Cap

6.78M

Low

2.155

Amount

891.08K

EV/EBITDA(TTM)

--

Total Shares

2.96M

EV

1.94M

EV/OCF(TTM)

--

P/S(TTM)

207.57

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

Show More

Events Timeline

(ET)

2025-12-03

08:50:00

Cardio Diagnostics Sets Final Payment Rate of $854 for Epi+Gen CHD and PrecisionCHD Tests

2025-07-22 (ET)

2025-07-22

09:13:48

Cardio Diagnostics gets CMS gapfill payment rates for cardiovascular tests

2025-07-08 (ET)

2025-07-08

09:17:19

Cardio Diagnostics, AGEPHA Pharma in deal for heart disease study

2025-06-10 (ET)

2025-06-10

08:56:06

Cardio Diagnostics secures Japanese patent for set of biomarkers

2025-05-29 (ET)

2025-05-29

08:41:00

Cardio Diagnostics regains compliance with Nasdaq

2025-05-08 (ET)

2025-05-08

08:40:45

Cardio Diagnostics announces 1-for-30 reverse stock split

2024-11-22 (ET)

2024-11-22

15:40:54

Cardio Diagnostics files to sell 1.24M shares of common stock for holders

News

Benzinga

Applied Optoelectronics Reports Strong Q4, Shares Surge

Benzinga

Etsy Sells Depop to eBay for $1.2 Billion

Businesswire

02-18Businesswire

Cardio Diagnostics to Host Investor Call on February 19, 2026

Newsfilter

02-17Newsfilter

Cardio Diagnostics to Host Investor Conference Call

Benzinga

Cardio Diagnostics Partners with India to Launch PrecisionCHD Coronary Test

NASDAQ.COM

01-07NASDAQ.COM

Cardio Diagnostics Launches PrecisionCHD Test in India with Aimil and Dr. Lal PathLabs

Valuation Metrics

The current forward P/E ratio for Cardio Diagnostics Holdings Inc (CDIO.O) is -0.41, compared to its 5-year average forward P/E of -3.95. For a more detailed relative valuation and DCF analysis to assess Cardio Diagnostics Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.95

Current PE

-0.41

Overvalued PE

1.48

Undervalued PE

-9.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

89.64

Current PS

9.88

Overvalued PS

273.12

Undervalued PS

-93.84

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

top loosers today

Intellectia · 908 candidates

Region: USPrice Change Pct: <= $-3.00

Ticker

Name

Market Cap$

Olema Pharmaceuticals Inc

1.70B

Oric Pharmaceuticals Inc

1.54B

Reviva Pharmaceuticals Holdings Inc

20.87M

EUDA Health Holdings Ltd

27.12M

Cardio Diagnostics Holdings Inc

9.68M

Traeger Inc

84.24M

stocks under 10 expected to gap up today

Intellectia · 26 candidates

Price: $1.00 - $10.00Volume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEGap Pattern: GapUpPre Market Price Change: >= $3.00

Ticker

Name

Market Cap$

Jiuzi Holdings Inc

1.66M

Cardio Diagnostics Holdings Inc

3.89M

Boxlight Corp

1.24M

Talkspace Inc

651.03M

PMGC Holdings Inc

1.46M

Mobilicom Ltd

58.61M

what stocks to short

Intellectia · 21 candidates

Short Ratio: MoreThan30PctBeta: HighRiskRsi 14: <= 40Month Price Change Pct: <= $0.00

Ticker

Name

Market Cap$

Robinhood Markets Inc

95.24B

Coinbase Global Inc

61.19B

MakeMyTrip Ltd

6.22B

Wix.Com Ltd

4.37B

Alphatec Holdings Inc

2.53B

Getty Images Holdings Inc

528.14M

Whales Holding CDIO

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cardio Diagnostics Holdings Inc (CDIO) stock price today?

The current price of CDIO is 2.29 USD — it has decreased -6.91

What is Cardio Diagnostics Holdings Inc (CDIO)'s business?

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

What is the price predicton of CDIO Stock?

Wall Street analysts forecast CDIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDIO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cardio Diagnostics Holdings Inc (CDIO)'s revenue for the last quarter?

Cardio Diagnostics Holdings Inc revenue for the last quarter amounts to 3.56K USD, decreased -21.21

What is Cardio Diagnostics Holdings Inc (CDIO)'s earnings per share (EPS) for the last quarter?

Cardio Diagnostics Holdings Inc. EPS for the last quarter amounts to -0.80 USD, decreased -31.03

How many employees does Cardio Diagnostics Holdings Inc (CDIO). have?

Cardio Diagnostics Holdings Inc (CDIO) has 15 emplpoyees as of March 23 2026.

What is Cardio Diagnostics Holdings Inc (CDIO) market cap?

Today CDIO has the market capitalization of 6.78M USD.